The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors
Open accessAbstract
Purpose: Adenoid cystic carcinomas (ACCs) represent a heterogeneous group of chemotherapy refractory tumors, with a subset demonstrating an aggressive phenotype. We investigated the molecular underpinnings of this phenotype and assessed the Notch1 pathway as a potential therapeutic target. Methods: We genotyped 102 ACCs that had available pathologic and clinical data. Notch1 activation was assessed by immunohistochemistry for Notch1 intracellular domain. Luciferase reporter assays were used to confirm Notch1 target gene expression in vitro. The Notch1 inhibitor brontictuzumab was tested in patient-derived xenografts from patients with ACC and in a patient with ACC who was enrolled in a phase I study. Results: NOTCH1 mutations occurred predominantly (14 of 15 patients) in the negative regulatory region and Pro-Glu-Ser-Thr–rich domains, the same two hotspots seen in T-cell acute lymphoblastic leukemias, and led to pathway activation in vitro. NOTCH1-mutant tumors demonstrated significantly higher levels of Notch1 pathway activation than wild-type tumors on the basis of Notch1 intracellular domain staining ( P = .004). NOTCH1 mutations define a distinct aggressive ACC subgroup with a significantly higher likelihood of solid subtype ( P < .001), advanced-stage disease at diagnosis ( P = .02), higher rate of liver and bone metastasis ( P ≤ .02), shorter relapse-free survival (median, 13 v 34 months; P = .01), and shorter overall survival (median 30 v 122 months; P = .001) when compared with NOTCH1 wild-type tumors. Significant tumor growth inhibition with brontictuzumab was observed exclusively in the ACC patient-derived xenograft model that harbored a NOTCH1 activating mutation. Furthermore, an index patient with NOTCH1-mutant ACC had a partial response to brontictuzumab. Conclusion: NOTCH1 mutations define a distinct disease phenotype characterized by solid histology, liver and bone metastasis, poor prognosis, and potential responsiveness to Notch1 inhibitors. Clinical studies targeting Notch1 in a genotype-defined ACC subgroup are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia
Weng, A. P., Ferrando, A. A., Lee, W., Morris, J. P., Silverman, L. B., Sanchez-Irizarry, C., Blacklow, S. C., Look, A. T., & Aster, J. C. (2004) · Science · doi:10.1126/science.1102160 · Cited by 2,715
Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1
Agrawal, N., Frederick, M. J., Pickering, C. R., Bettegowda, C., Chang, K., Li, R. J., Fakhry, C., Xie, T.-X., Zhang, J., Wang, J., et al. (2011) · Science · doi:10.1126/science.1206923 · Cited by 1,697
Self-citationWhole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
Puente, X. S., Pinyol, M., Quesada, V., Conde, L., Ordóñez, G. R., Villamor, N., Escaramis, G., Jares, P., Beà, S., González-Díaz, M., et al. (2011) · Nature · doi:10.1038/nature10113 · Cited by 1,514
Therapeutic antibody targeting of individual Notch receptors
Wu, Y., Cain-Hom, C., Choy, L., Hagenbeek, T. J., de Leon, G. P., Chen, Y., Finkle, D., Venook, R., Wu, X., Ridgway, J., et al. (2010) · Nature · doi:10.1038/nature08878 · Cited by 720
O'Neil, J., Grim, J., Strack, P., Rao, S., Tibbitts, D., Winter, C., Hardwick, J., Welcker, M., Meijerink, J. P., Pieters, R., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070876 · Cited by 663
Pickering, C. R., Zhang, J., Yoo, S. Y., Bengtsson, L., Moorthy, S., Neskey, D. M., Zhao, M., Ortega Alves, M. V., Chang, K., Drummond, J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0537 · Cited by 559
Self-citationThe SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia
Thompson, B. J., Buonamici, S., Sulis, M. L., Palomero, T., Vilimas, T., Basso, G., Ferrando, A., & Aifantis, I. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070872 · Cited by 480
The mutational landscape of adenoid cystic carcinoma
Ho, A. S., Kannan, K., Roy, D. M., Morris, L. G. T., Ganly, I., Katabi, N., Ramaswami, D., Walsh, L. A., Eng, S., Huse, J. T., et al. (2013) · Nature Genetics · doi:10.1038/ng.2643 · Cited by 467
Oncogenic and tumor suppressor functions of Notch in cancer: it’s NOTCH what you think
Lobry, C., Oh, P., & Aifantis, I. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20111855 · Cited by 356
Whole exome sequencing of adenoid cystic carcinoma
Stephens, P. J., Davies, H. R., Mitani, Y., Van Loo, P., Shlien, A., Tarpey, P. S., Papaemmanuil, E., Cheverton, A., Bignell, G. R., Butler, A. P., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67201 · Cited by 271
Self-citationLi, L., Milner, L. A., Deng, Y., Iwata, M., Banta, A., Graf, L., Marcovina, S., Friedman, C., Trask, B. J., Hood, L., et al. (1998) · Immunity · doi:10.1016/s1074-7613(00)80457-4 · Cited by 269
Multiple niches for Notch in cancer: context is everything
Weng, A. P., & Aster, J. C. (2004) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2003.11.004 · Cited by 210
Protein Degradation: Four E3s For The Notch Pathway
Lai, E. C. (2002) · Current Biology · doi:10.1016/s0960-9822(01)00679-0 · Cited by 180
Zanotti, S., & CANALIS, E. M. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01285-09 · Cited by 158
Stoeck, A., Lejnine, S., Truong, A. S., Li, P., Wang, H., Zang, C., Yuan, J., Ware, C., Maclean, J. K. F., Garrett-Engele, P. W., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0830 · Cited by 144
Grego-Bessa, J., Díez, J., & de la Pompa, J. L. (2004) · Cell Cycle · doi:10.4161/cc.3.6.949 · Cited by 138
NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL
Sulis, M. L., Williams, O., Palomero, T., Tosello, V., Pallikuppam, S., Real, P. J., Barnes, K., Zuurbier, L. C., Meijerink, J. P. P., & Ferrando, A. A. (2008) · Blood · doi:10.1182/blood-2007-12-130096 · Cited by 134
Notch signaling and the bone marrow hematopoietic stem cell niche
Weber, J. M., & Calvi, L. M. (2009) · Bone · doi:10.1016/j.bone.2009.08.007 · Cited by 133
Notch signaling and new therapeutic options in liver disease
Morell, C. M., & Strazzabosco, M. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.11.028 · Cited by 115
Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry
Kluk, M., Ashworth, T. D., Wang, H., Knoechel, B., Mason, E. F., Morgan, E. A., Dorfman, D. M., Pinkus, G., Weigert, O., Hornick, J. L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067306 · Cited by 111
Altered Notch Ligand Expression in Human Liver Disease
Nijjar, S. S., Wallace, L. M., Crosby, H. A., Hübscher, S. G., & Strain, A. J. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)61116-9 · Cited by 104
Development and characterization of xenograft model systems for adenoid cystic carcinoma
Moskaluk, C. A., Baras, A. S., Mancuso, S. A., Fan, H., Davidson, R. J., Dirks, D. C., Golden, W. L., & Frierson, H. F. (2011) · Laboratory Investigation · doi:10.1038/labinvest.2011.105 · Cited by 66
Ross, J. S., Wang, K., Rand, J. V., Sheehan, C. E., Jennings, T. A., Al-Rohil, R. N., Otto, G. A., Curran, J. C., Palmer, G. A., Downing, S. R., et al. (2014) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000102 · Cited by 64
Frierson, H. F., & Moskaluk, C. A. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69070 · Cited by 50
Expression and significance of notch signaling pathway in salivary adenoid cystic carcinoma
Bell, D., Hanna, E. Y., Miele, L., Roberts, D. B., Weber, R. S., & El‐Naggar, A. K. (2013) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2013.10.001 · Cited by 30
Self-citation
Cited by
Notch signaling pathway: architecture, disease, and therapeutics
Zhou, B., Lin, W., Long, Y., Yang, Y., Zhang, H., Wu, K., & Chu, Q. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00934-y · Cited by 1,114
Management of Salivary Gland Malignancy: ASCO Guideline
Geiger, J. L., Ismaila, N., Beadle, B., Caudell, J. J., Chau, N., Deschler, D., Glastonbury, C., Kaufman, M., Lamarre, E., Lau, H. Y., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00449 · Cited by 441
Ferrarotto, R., Eckhardt, G., Patnaik, A., LoRusso, P., Faoro, L., Heymach, J. V., Kapoun, A. M., Xu, L., & Munster, P. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy171 · Cited by 138
Self-citation
Metadata
- Authors
- Ferrarotto, R., Mitani, Y., Diao, L., Guijarro, I., Wang, J., Zweidler-McKay, P., Bell, D., William, W. N., Glisson, B. S., Wick, M. J., Kapoun, A. M., Patnaik, A., Eckhardt, G., Munster, P., Faoro, L., Dupont, J., Lee, J. J., Futreal, A., El-Naggar, A. K., & Heymach, J. V.
- Venue
- Journal of Clinical Oncology
- Published
- 2017-01-20
- Volume
- 35
- Issue
- 3
- Pages
- 352-360
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2553335953
- Cited by
- 253
- References
- 25
- FWCI
- 16.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.